NFE2L2 and cancer: Given that NRF2 R34L has the shortest half-life and is significantly negatively selected for in cancer, future studies into the potential periodicity of NRF2-R34L activation may offer clues into the hypothesis behind constitutive versus intermittent NRF2 activation in cancer prevention and promotion.